Clinical features and outcome in HIV-associated multicentric Castleman's disease

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2481-2486

  Bower, Mark ^a   Newsom Davis, Tom ^a   Naresh, Kikkeri ^b   Merchant, Shairoz ^a   Lee, Belinda ^a   Gazzard, Brian ^a   Stebbing, Justin ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON; RITUXIMAB; VINBLASTINE;

ADULT; AGED; ARTICLE; ASCITES; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COUGHING; EDEMA; FEMALE; FEVER; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; JAUNDICE; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTRIC CASTLEMAN DISEASE; NOSE OBSTRUCTION; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMORBIDITY; DATABASES, FACTUAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959300575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1909     Document Type: Article

References (31)

1. Menke DM, Tiemann M, Camoriano JK, et al: Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol 105:268-276, 1996 (Pubitemid 26077366)
2. Dupin N, Diss TL, Kellam P, et al: HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-1412, 2000 (Pubitemid 30099854)
3. Du MQ, Liu H, Diss TC, et al: Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-2136, 2001 (Pubitemid 32239096)
4. Ost A, Baroni CD, Biberfeld P, et al: Lymphadenopathy in HIV infection: Histological classification and staging. APMIS Suppl 8:7-15, 1989 (Pubitemid 19171815)
5. Dupin N, Fisher C, Kellam P, et al: Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96:4546-4551, 1999 (Pubitemid 29190373)
6. Powles T, Stebbing J, Bazeos A, et al: The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 20:775-779, 2009
7. Du MQ, Bacon CM, Isaacson PG: Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 60:1350-1357, 2007 (Pubitemid 350247250)
8. Gérard L, Bérezné A, Galicier L, et al: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350-3356, 2007 (Pubitemid 47325622)
9. Oksenhendler E: HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 4:16-21, 2009
10. Goris RJ, te Boekhorst TP, Nuytinck JK, et al: Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 120:1109-1115, 1985
11. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Peto R, Pike Mc, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
13. Bower M: How I treat HIV-associated multicentric Castleman disease. Blood 116:4415-4421, 2010
14. Dargent JL, Lespagnard L, Sirtaine N, et al: Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern. APMIS 115:869-874, 2007 (Pubitemid 47030104)
15. Bower M, Powles T, Williams S, et al: Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147: 836-839, 2007 (Pubitemid 351664423)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Mylona EE, Baraboutis IG, Lekakis LJ, et al: Multicentric Castleman's disease in HIV infection: A systematic review of the literature. AIDS Rev 10:25-35, 2008 (Pubitemid 351524049)
18. Grandadam M, Dupin N, Calvez V, et al: Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175:1198-1201, 1997
19. Oksenhendler E, Carcelain G, Aoki Y, et al: High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96:2069-2073, 2000
20. Corbellino M, Bestetti G, Scalamogna C, et al: Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473-3475, 2001
21. Boivin G, Côté S, Cloutier N, et al: Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol 68:399-403, 2002
22. Casper C, Nichols WG, Huang ML, et al: Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632-1634, 2004 (Pubitemid 38268952)
23. Berezne A, Agbalika F, Oksenhendler E: Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 103:4368-4369, 2004; author reply 4369 (Pubitemid 38685387)
24. Marcelin AG, Motol J, Guihot A, et al: Relationship between the quantity of Kaposi sarcomaassociated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis 196:1163-1166, 2007 (Pubitemid 47580271)
25. Oksenhendler E, Duarte M, Soulier J, et al: Multicentric Castleman's disease in HIV infection: A clinical and pathological study of 20 patients. AIDS 10:61-67, 1996 (Pubitemid 26016404)
26. Marcelin AG, Aaron L, Mateus C, et al: Rituximab therapy for HIV-associated Castleman disease. Blood 102:2786-2788, 2003 (Pubitemid 37248847)
27. Neuville S, Agbalika F, Rabian C, et al: Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 79:337-339, 2005 (Pubitemid 41098853)
28. Buchler T, Dubash S, Lee V, et al: Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: Report of two cases. AIDS 22:1685-1687, 2008
29. Oksenhendler E, Boulanger E, Galicier L, et al: High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331-2336, 2002 (Pubitemid 34525417)
30. Matthews GV, Bower M, Mandalia S, et al: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 96:2730-2734, 2000
31. Casper C, Krantz EM, Corey L, et al: Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 198:23-30, 2008 (Pubitemid 351920285)